Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telaprevir + rilpivirine
- Development stage
- Unknown
- Lead developer
- Vertex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Telaprevir + rilpivirine** is an investigational co-administration of two orally administered small-molecule antivirals evaluated in a Phase 1 healthy-volunteer pharmacokinetic interaction study. Telaprevir is a direct-acting hepatitis C virus NS3/4A serine protease inhibitor, while rilpivirine, previously designated **TMC278**, is a non-nucleoside inhibitor of HIV-1 reverse transcriptase. The combination was studied to characterize reciprocal effects on exposure at steady state, rather than as a marketed fixed-dose product or an established therapeutic regimen for HIV and hepatitis C coinfection.
- Brand names
- IncivekIncivoEdurant
- Other names
- rilpivirine + telaprevirtelaprevir + TMC278TMC278 + telaprevir
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseNS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on telaprevir + rilpivirine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telaprevir + rilpivirine.